Ripple Therapeutics Corporation

Published purpose

Ripple Therapeutics Corporation is a clinical stage, privately held company that is focused on ophthalmic therapeutics with controllable, sustainable drug delivery. The Ripple pipeline currently has a variety of conjugates under development targeting key ocular indications such as glaucoma, DME and GA-AMD. Scientific and engineering resources will perform work on the manufacturability of Ripple’s prostaglandin conjugates (RTC-PGs) for the treatment of Primary Open Angle Glaucoma. The project will require analysis of data generated from chemistry, manufacturing and controls (CMC) development to develop the manufacturing know-how for a robust and sustainable licensing and commercialization process that can be applied to all pipeline products.